美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Brincidofovir	Tablet	I (Basket)	50	50 mM sodium phosphate buffer, pH 6.4 + 0.3% SDS	900	5, 10, 15, 20, 30, 45, 60, 75 and 90	2023/07/07
Brincidofovir	Suspension	II (Paddle)	50	0.05 M Sodium Phosphate Monobasic, Monohydrate Buffer, pH 6.4 + 0.05% Tween 80	900	5, 10, 15, 20, 30, 45, 60, 75 and 90	2023/07/07
Brinzolamide	Ophthalmic Suspension			Develop a method to characterize in vitro release			2011/09/01
Brivaracetam	Tablet	II (Paddle	50	Phosphate Buffer, pH 6.4	2.5 and 5 mg tablets: 500 mL; 10, 25, 50, 75 and 100 mg tablets: 900 mL	5, 10, 15, 20 and 30	2016/07/28
Bromocriptine Mesylate	Tablet			Refer to USP			2007/07/25
Budesonide	Tablet (Extended Release)	II (Paddle)	100	Acid Stage: 0.1 M HCl containing 0.5% Macrogol Cetostearyl Ether; Buffer Stage: pH 7.2 phosphate buffer containing 0.5% Macrogol Cetostearyl Ether.	Acid Stage: 500 mL ; Buffer Stage: 1000 mL	Acid Stage: 2 hours; Buffer Stage: 1, 2, 4, 6, 8 and 10 hours	2015/04/02
Budesonide	Capsule	II (Paddle) with sinker	75	Acid stage: 0.1 N HCl; Buffer stage: Phosphate Buffer, pH 7.5	Acid stage: 1000; Buffer stage: 1000	Acid stage: 2 hours; Buffer stage: 0.25, 0.5, 1, 2, 4, 6 and 8 hours	2015/02/25
Budesonide	Suspension	II (Paddle)	50	0.25% SDS in 0.009 N HCl	500	5, 10, 15, 20, 30, 45 and 60	2026/01/28
Bumetanide	Tablet			Develop a dissolution method			2024/01/03
Bupivacaine	Solution (Extended Release), Infiltration	II (Paddle)	50	0.025 M Sodium Phosphate Buffer with 0.03% Sodium Dodecyl Sulfate (SDS), pH 7.4	900	1, 2, 4, 8, 12, 16, 24, 36 and 48 hours	2022/07/07
Bupivacaine; Meloxicam	Solution, Extended Release			Develop a method to characterize in vitro release			2025/09/08
Buprenorphine	Solution, Extended Release			Develop a dissolution method			2026/03/25
Buprenorphine	Film, Transdermal (Extended Release)	VI (Cylinder) with adapter, if needed	50	0.9% Sodium Chloride at 32°C	600	0.5,1, 2, 4, 6, 8,12, 16 and 24 hours	2013/05/09
Buprenorphine (64 mg, 96 mg, and 128 mg)	Solution, Extended Release	I (Basket)	50	100 mM Citric Acid Buffer, pH 4.0	500	1, 2, 4, 6, 10, 12, 24, 48, 72 and 96 hours	2026/03/25
Buprenorphine (8 mg, 16 mg, 24 mg, and 32 mg)	Solution, Extended Release	I (Basket)	50	100 mM Citric Acid Buffer, pH 3.0	900	1, 2, 4, 6, 10, 12, 24, 48, 72, 96, 168 and 192 hours	2026/03/25
Buprenorphine HCl	Film (Buccal)	I (Basket) 100 mL round bottom vessel	100	0.05M NaH2PO4.H2O Phosphate Buffer, pH 4.5	60	10, 15, 20, 30, 45 and 60	2016/10/20
Buprenorphine HCl	Implant	II (Paddle)	50	Water	900	1, 4, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours	2016/07/28
Buprenorphine HCl	Tablet (Sublingual)			Develop a dissolution method			2023/09/15
Buprenorphine HCl/Naloxone HCl	Tablet (Sublingual)			Develop a dissolution method			2023/09/15
Buprenorphine HCl/Naloxone HCl	Film (Sublingual)	V (Paddle over Disk) with 56 mm, 40 mesh stainless steel disk.	100	Acetate Buffer, pH 4.0 (12.5mM Sodium acetate trihydrate and 60mM glacial acetic acid. Adjust the pH with glacial acetic acid or ammonium hydroxide).	900	1, 2, 3, 5, 7 and 10	2013/10/31